1128 related articles for article (PubMed ID: 11089434)
21. Retrospective analysis of 34 cases of hairy cell leukemia treated with interferon-alpha and/or 2-chlorodeoxyadenosine.
Zaja F; Fanin R; Silvestri F; Russo D; Infanti L; Baccarani M
Haematologica; 1997; 82(4):468-70. PubMed ID: 9299866
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients.
Maloisel F; Benboubker L; Gardembas M; Coiffier B; Divine M; Sebban C; Blanc M; Abgrall JF; Lederlin P; Harousseau JL; Blaise AM; Grosbois B; Morice P; Ghandour C; Castaigne S
Leukemia; 2003 Jan; 17(1):45-51. PubMed ID: 12529659
[TBL] [Abstract][Full Text] [Related]
23. Recombinant alpha-interferon (alpha-IFN) for progressive hairy-cell leukemia (HCL): a study in previously untreated nonsplenectomized patients.
Schwarzinger I; Bettelheim P; Chott A; Herold C; Hinterberger W; Köller U; Kos M; Neumann E; Radaszkiewicz T; Lechner K
Wien Klin Wochenschr; 1988 Jan; 100(2):47-51. PubMed ID: 3348041
[TBL] [Abstract][Full Text] [Related]
24. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
25. The treatment of hairy cell leukemia: an update.
Golomb HM; Ratain MJ; Mick R; Daly K
Leukemia; 1992; 6 Suppl 2():24-7. PubMed ID: 1349662
[TBL] [Abstract][Full Text] [Related]
26. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
[TBL] [Abstract][Full Text] [Related]
27. Hairy cell leukemia: a model for studying the B cell family of diseases.
Al-Katib A; Berman E; Black P; Koziner B
Semin Oncol; 1986 Dec; 13(4 Suppl 5):48-54. PubMed ID: 3492047
[TBL] [Abstract][Full Text] [Related]
28. Treatment of hairy-cell leukemia: current views.
Tallman MS; Peterson LC; Hakimian D; Gillis S; Polliack A
Semin Hematol; 1999 Apr; 36(2):155-63. PubMed ID: 10319384
[TBL] [Abstract][Full Text] [Related]
29. [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
Zák P; Chrobák L; Dĕdic K; Podzimek K
Vnitr Lek; 2000 Oct; 46(10):697-703. PubMed ID: 11344629
[TBL] [Abstract][Full Text] [Related]
30. Treatment of hairy cell leukaemia with recombinant alpha interferon.
Romeril KR; Carter JM; Green GJ; Beard ME; Heaton DC; Newhook CH; Gibbons SS; Reddy J
N Z Med J; 1989 Apr; 102(866):186-8. PubMed ID: 2652008
[TBL] [Abstract][Full Text] [Related]
31. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
32. [Hairy cell leukemia successfully treated with deoxycoformycin].
Matsuda A; Jinnai I; Mizuno H; Sakata T; Kusumoto S; Kayano H; Takeuchi H; Bessho M; Saito M; Katayama I
Rinsho Ketsueki; 1992 Nov; 33(11):1685-90. PubMed ID: 1469784
[TBL] [Abstract][Full Text] [Related]
33. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
34. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.
Else M; Ruchlemer R; Osuji N; Del Giudice I; Matutes E; Woodman A; Wotherspoon A; Swansbury J; Dearden C; Catovsky D
Cancer; 2005 Dec; 104(11):2442-8. PubMed ID: 16245328
[TBL] [Abstract][Full Text] [Related]
35. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
36. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia.
Benz R; Siciliano RD; Stussi G; Fehr J
Eur J Haematol; 2009 Mar; 82(3):194-200. PubMed ID: 19077050
[TBL] [Abstract][Full Text] [Related]
38. Early response to alpha interferon in a patient affected by hairy cell leukemia.
Di Raimondo F; Murolo D; Milone G; Cacciola E; Giustolisi R
Haematologica; 1992; 77(4):355-6. PubMed ID: 1427445
[TBL] [Abstract][Full Text] [Related]
39. Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy.
Pamuk GE; Pamuk ON; Başlar Z; Ongören S; Soysal T; Ferhanoğlu B; Aydin Y; Ulkü B; Aktuğlu G; Akman N
Ann Hematol; 2002 Aug; 81(8):436-40. PubMed ID: 12224000
[TBL] [Abstract][Full Text] [Related]
40. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
